NewGenIvf Group Limited
NewGenIvf Group Limited Class A Ordinary Shares is the publicly traded equity of NewGenIvf Group Limited, a healthcare-focused company that provides assisted reproductive services in Asia. The business centers on fertility care, including in vitro fertilization, intracytoplasmic sperm injection, egg donation, embryo culture, hormone and genetic testing, hysteroscopy, sperm processing, and egg freezing. It also offers surrogacy-related and ancillary support services for individuals and couples seeking fertility treatment. NewGenIvf Group Limited operates across multiple markets in the Asia-Pacific region, with services available in locations such as Thailand, Cambodia, Hong Kong, and Kyrgyzstan. The company functions as a specialized reproductive medicine platform within the broader healthcare services sector, serving patients through a cross-border clinical network and a range of diagnostic and treatment solutions.
$0.28
+$0.03 (+11.60%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-226.95% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 13.0% YoY. Margins deteriorated 205.6pp alongside, both lines moving the wrong way.
ROIC dropped from -27.75% to -63.32%, capital efficiency is deteriorating. Negative free cash flow of -$17M. The business is consuming cash, not generating it.
0.0x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$5M
▼ -13.0% YoY
Net Income (TTM)
$10M
▲ +2152.0% YoY
Op. Margin
-226.95%
▼ -205.6pp YoY
ROIC
-63.32%
▼ -35.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$17M
▼ -100.5% YoY
Op. Cash Flow (TTM)
-$11M
▼ -32.2% YoY
Net Debt
$4M
Cash & Equiv.
$759K
3Y CAGR: -7.4%
Continue Research
Is NewGenIvf Group (NIVF) overvalued?
At a P/E of 0.0, NewGenIvf Group (NIVF)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, NewGenIvf Group scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is NewGenIvf Group a high-quality business?+
NewGenIvf Group scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -226.9% operating margin and a -63.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is NewGenIvf Group a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh NIVF's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Medical Care Facilities
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.